Proposed platform targets brain immune balance, microglial function and regenerative signaling, inspired by emerging Alzheimer’s research
HUNTINGTON BEACH, California — October 5, 2026 — Lionheart Health, Inc. is preparing a provisional patent application describing proposed combinations of bioelectric stimulation, biologics and targeted protein expression intended to support healthier brain aging. The research concept focuses on restoring balanced communication among microglia, astrocytes and neurons, with the long-term objective of improving the brain’s ability to respond to damage while limiting harmful inflammation.
The proposed application is inspired in part by new research examining the PD-1/PD-L1 immune checkpoint pathwayin Alzheimer’s disease. Lionheart’s approach would investigate whether precisely controlled bioelectric signals, combined with selected biologics, can influence this pathway and complementary regenerative mechanisms.
New research points to the brain’s immune control system
A study by Park and colleagues, published in Science Advances in September 2026, investigated local PD-L1 blockade in an Alzheimer’s disease mouse model. Researchers reported improved microglial responses to damage, increased expression of the homeostasis-associated receptor P2RY12 and reduced abnormal neuronal hyperactivity. Astrocyte-specific PD-L1 knockdown produced similar effects, supporting a role for astrocytes in regulating these interactions. These were preclinical findings, not evidence of an effective human treatment.
For Lionheart, the study provides a research rationale for exploring brain immune regulation alongside regenerative protein signaling. It does not establish that bioelectric stimulation can reproduce checkpoint blockade or achieve the same outcomes.
A proposed combination of bioelectric signals and biologics
Lionheart’s proposed patent strategy would describe methods for evaluating bioelectric stimulation before, during or after administration of selected biologics, including candidate proteins, peptides, antibodies and cell-derived products.
The central research question is whether these combinations can produce a more favorable brain cellular environment than either component alone. Proposed areas of investigation include:
-
Immune checkpoint modulation: Testing whether selected stimulation parameters alter PD-1/PD-L1 expression or signaling in relevant brain cells.
-
Microglial function: Measuring responses to cellular damage, amyloid uptake and clearance, and markers such as P2RY12.
-
Regenerative protein expression: Evaluating Klotho, BDNF and GDF10 as candidate components of a broader brain repair and resilience strategy.
-
Biologic enhancement: Determining whether stimulation changes the production, release or activity of selected biologic factors.
-
Controlled treatment sequencing: Comparing stimulation and biologics individually with combinations delivered in defined sequences.
These targets represent proposed experiments. Lionheart has not established that its devices regulate glial PD-1/PD-L1, restore exhausted microglia or clear amyloid in humans.
Supporting cleanup while preserving immune balance
The intended development goal is to help the brain’s immune cells respond appropriately to damage while preserving the controls that protect healthy tissue.
This requires measuring both potential benefits and unwanted effects. A candidate combination that increases amyloid uptake would also need to demonstrate that it does not increase inflammatory injury, impair neuronal survival or disrupt normal brain signaling.
Lionheart’s proposed research framework would therefore assess microglial activity, astrocyte responses, inflammatory markers, neuronal function and cell viability together. Any claim of enhanced performance would require direct comparisons against stimulation alone, biologics alone and appropriate controls.
From patent preparation to experimental validation
Initial development would focus on laboratory models containing relevant brain cell populations, followed by appropriate preclinical studies if results support further investigation. Delivery to the intended brain cells, reproducible biological activity and safety would be central development questions.
The planned provisional application would document the proposed combinations, stimulation parameters, delivery approaches and methods for measuring biological responses. Its preparation does not mean an application has been filed or that patent rights have been granted.
Lionheart’s long-term objective is to develop evidence-based combinations that unite bioelectric control with biologic support for brain resilience and healthy aging.
Research and development notice: The approaches described are investigational. Safety and effectiveness for Alzheimer’s disease, amyloid clearance or reversal of brain aging have not been established in humans. This announcement describes patent preparation and proposed research, rather than an available treatment for these conditions.
Scientific reference: Park et al. “Targeting glial PD-1/PD-L1 restores microglial homeostasis and reduces neuronal hyperactivity in an Alzheimer’s disease model.” Science Advances 12(38), eadx0731 (2026). Read the study.